• Publications
  • Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
TLDR
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Detection of Merkel cell polyomavirus in Merkel cell carcinoma and Kaposi's sarcoma
TLDR
The data suggest that the prevalence of MCPyV is low in Japan, and is at least partly associated with the pathogenesis of Merkel cell carcinoma.
Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial
Tildrakizumab is a high‐affinity, humanized, IgG1/κ, anti‐interleukin (IL)‐23p19 monoclonal antibody that does not bind human IL‐12 or p40 is being developed for the treatment of chronic plaque
Nuclear localization of Merkel cell polyomavirus large T antigen in Merkel cell carcinoma.
TLDR
The expression of large T antigen in vitro and in vivo and sequence analyses suggest that the nuclear localization signal is highly conserved and functional in Merkel cell carcinoma cases.
Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial
TLDR
Ustekinumab was efficacious and generally well‐tolerated in Japanese patients with moderate‐to‐severe plaque‐type psoriasis through 72 weeks, consistent with those reported in the global, phase 3 studies.
Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families.
TLDR
The data indicate that genetic differences in transcriptional activity of the IL4 gene influence AD predisposition, particularly in Japanese, because of a high frequency of the T allele.
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
TLDR
Infliximab could provide a sustained Improvement effect on skin and joint symptoms, and accordingly contributed to a sustained improvement in the QOL of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus.
TLDR
Genotyping of 419 families from six populations revealed that coding single-nucleotide polymorphisms of HCR formed a conserved allele HCR*WWCC that associated highly significantly with psoriasis and with the HLA-Cw6 allele in all populations.
Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab
TLDR
The present results demonstrate that a PASI 90 response is necessary to achieve a Dermatology Life Quality Index (DLQI) of 0 or 1, and infliximab is considered a useful drug in meeting the treatment goal of achieving a DLQI of0 or 1 through the attainment of a Pasmi 90 response.
Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
Ixekizumab, an anti‐IL‐17A monoclonal antibody, demonstrated a high level of efficacy in moderate‐to‐severe plaque psoriasis (PP) patients.
...
1
2
3
4
5
...